Name: South America Constipation Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: PH2279
Price: 3750 USD
Availability: InStock

 South America Constipation Market Size Share Report Analysis 2022 |

 South America Constipation Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>South America Constipation Market is segmented By Disease Type (Opioid-induced constipation, Chronic idiopathic constipation, Irritable bowel syndrome with constipation), By Therapeutic (Chloride channel activators, Laxatives, GC-C Agonists, Peripherally Acting Mu-Opioid Receptor Antagonists, 5-HT4 Receptor Agonists), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Country (Brazil, Argentina, Colombia, Peru, Rest of South America)&nbsp; and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2022-2029</h2>

&nbsp;

South America Constipation Market&nbsp;is expected to grow at a&nbsp; high&nbsp;<a href="https://www.datamintelligence.com/download-sample/south-america-constipation-market">CAGR</a> during the forecasting period (2022-2029).

South America Constipation Market Scop

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			Market&nbsp;CAGR
			</td>
			<td>
			High
			</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Disease Type,&nbsp;By Therapeutic ,By Distribution Channel,&nbsp;By Application,&nbsp;and By Region
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Fastest Growing Region
			</td>
			<td>
			Asia Pacific
			</td>
		</tr>
		<tr>
			<td>
			Largest Market Share&nbsp;
			</td>
			<td>
			North America
			</td>
		</tr>
	</tbody>
</table>

Get A Free Sample <a href="https://www.datamintelligence.com/download-sample/south-america-constipation-market">Click Here</a>

Constipation is the most common chronic gastrointestinal disorder in adults. It is more common in women, the elderly, and children. Specifically, constipation with no known cause affects females more often than males.&nbsp;As per DataM Intelligence, South America Constipation Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global South America Constipation Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. South America Constipation Market in the United States and Canada produces the utmost share. Whereas the European South America Constipation Market is projected to continue its presence globally during the period of 2022- 2029.

Market&nbsp;Dynamics

The South America constipation market is growing owing to several factors such as the rising geriatric population, treatment or new drugs development and rising prevalence of IBS-C, OIC, and chronic constipation.

Rising treatments and latest drugs in market and rising prevalence of IBS-C, OIC, and chronic constipation is expected to drive market growth.

In South American countries, the aging population is expected to accelerate significantly. Constipation is a chronic, multifunctional problem that is more prevalent in women and the elderly. Its incidence varies from 7.72% to 42.86% in individuals older than 70 years.

South America&rsquo;s population aged 65 or over will triple to 18 percent by 2050. Between 2021 and 2050, Latin America and the Caribbean will see an increase in their share of the world&rsquo;s older population from 8 percent in 2021 to 9 percent in 2050.

Rising living standards and better access to quality health care have increased Latin Americans&#39; life expectancy to close to 75 years. Chileans and Costa Ricans can expect to live more than 80 years, slightly longer than United States residents.

According to a Brazil study, the prevalence of IC in the elderly in this study was 14.23%. The prevalence of IC and its associated factors is more frequently observed in females. The association with IC was found in the elderly with chronic diseases, cancer, opioid use, and lack of fluids influencing fecal cake strength.

Data from a national study on the increased prevalence of constipation in the elderly showed that IH&#39;s prevalence was greater in females, representing 89.2% of the analysed sample of constipated individuals, and in the elderly 80 years old or older, females constituted 67.6%.

Dependence on over-the-counter drugs is expected to hamper the market growth.

Increasing Dependence on Majority of Over-the-Counter (OTC) Drugs is the main the factors hampering the growth of the market.

Industry Analysis

The South America constipation market provides in-depth analysis of the market based on various industry factors such as Porter&rsquo;s Five Forces, Pipeline Analysis, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis, Product Innovation, Unmet Needs, Comparative Scenario.

Segment Analysis

Irritable bowel syndrome segment is expected to hold the largest market share in South America constipation market

Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Symptoms of IBS include cramping, abdominal pain, bloating, gas, diarrhea, and constipation. Diagnosis of irritable bowel syndrome is made by tests such as blood tests, stool tests, endoscopic procedures, and external imaging procedures. In contrast, the treatment includes relieving the patient from the symptoms and improving the quality of life.

Increasing launches of various pipeline drugs mainly drive the irritable bowel syndrome with constipation (IBS-C) market for the treatment over the forecast period. The rising prevalence of gastrointestinal diseases and disorders, unhealthy diet, anxiety, and changing lifestyle in South America also drive the market&#39;s growth.

In Uruguay, according to a study, the overall prevalence of 10.9% (14.8% in women and 5.4% in men)&mdash;58% with IBS-C and 17% with IBS-D. In 72% of the cases, the age of onset was &lt; 45 years.

A study from Venezuela reported an IBS prevalence of 16.8%, with 81.6% of those affected being women and 18.4% men. Studies on indigenous populations in Latin America revealed a high prevalence of IBS, which was similar to that in the rest of the population.

The major market players adopt various key strategies such as partnerships, collaborations, and product launches to gain a competitive advantage. For instance,

In September 2019, Ardelyx, Inc., a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, announced that the U.S. Food and Drug Administration had approved IBSRELA (tenapanor), a 50 mg, a twice-daily oral pill for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is a minimally-absorbed small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium-hydrogen exchanger NHE3, resulting in increased bowel movements a decrease in abdominal pain for IBS-C patients.

Geographical Analysis

Brazil region holds the largest market share in the South America constipation market

Constipation is a common problem with an incidence between 40% and 90% of patients treated with opioids and may appear after a single dose. The consequence of constipation over time is related to increased morbidity and mortality and worsening of patients&#39; quality of life.

Growing awareness and rising incidence and prevalence of chronic idiopathic constipation - CIC are the major factors driving Brazil&#39;s constipation drugs market. Growth in demand for CIC drugs in South America, coupled with the huge gap of unmet needs in the region, is expected to serve as a significant opportunity in the constipation market during the forecast period.

Huge investments in research and development for the opioid-induced constipation market are the major opportunity for Brazil&#39;s market growth.

Side effects associated with laxatives and lack of proper treatment options are helping the market growth.

Due to the lack of immediate-release opioids for oxycodone and hydromorphone, escapes are empirically made with morphine in Brazil. However, the pharmacological association of agents acting on the same type of receptor is not recommended.

Non-medical use of opioids in Brazil may be more prevalent than previously recognized. Proper measurement and evaluation of opioid misuse across Brazil and other Latin American countries are critical to understanding and preventing opioid-related harms.

Competitive Landscape

Some of the major players in the constipation market include Takeda Pharmaceutical Company Ltd, Abbott Laboratories, AstraZeneca, Sanofi, Bayer AG, Daewoong Pharmaceuticals, Bausch Health Companies Inc., Janssen Pharmaceutical, among others.

Manufacturers&#39; large investments in developing therapeutic drugs for constipation are expected to fortify South America&#39;s market. These ardent efforts by the manufacturers of therapeutic drugs for constipation treatment have aided the constipation market&#39;s growth.

The key players are adopting various strategies such as product launches, mergers &amp; acquisitions, partnerships, and collaborations, contributing to the growth of the sports medicine market globally. For instance,

In January 2019, Ironwood Pharmaceuticals Inc. and Allergan plc settled a patent dispute with Mylan NV over the generic maker&#39;s version of Linzess, a drug that treats irritable bowel syndrome constipation.

In April 2019, Takeda Pharmaceuticals U.S.A., Inc., (&ldquo;Takeda&rdquo;) announced that Motegrity&trade; (prucalopride), a once-daily, oral treatment option, is now commercially available by prescription for adults with chronic idiopathic constipation (CIC).

South America Constipation Market &ndash; Key Companies to Watch

Takeda Pharmaceutical Company Ltd.:

Overview: Takeda Pharmaceutical Co Ltd is a pharmaceutical company that is research based and develops, manufactures and markets pharmaceutical drugs. They provide products in various fields such as oncology, gastrointestinal, plasma-derived therapies, vaccines etc.&nbsp; Takeda was founded in 1789 and is headquartered in Tokyo, Japan.

Product Portfolio: 

Motegrity: It is a serotonin-4 receptor agonist used as medication for chronic idiopathic constipation. It is an oral treatment that is consumed once daily.

Key Developments: In October 2021, Takeda acquired&nbsp;Gamma Delta Therapeutics along with its programme on T cell immunotherapy.

The South America constipation market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

&nbsp;

<h3 style="background:#eeeeee;border:1px solid #cccccc;padding:5px 10px;">Frequently Asked Questions</h3>

What is the Projected CAGR value of the South America Constipation Market?

South America Constipation Market is expected to grow at a&nbsp;CAGR of high&nbsp;during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America&nbsp;region Controls&nbsp;the&nbsp;South America Constipation Market&nbsp;during 2022-2029.

Which is the fastest growing region in the South America Constipation Market?

Among all regions,&nbsp;Asia Pacific&nbsp;is the fastest growing market share during the forecast period.

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topic&#39;s</h3>

<a href="https://www.datamintelligence.com/research-report/opioid-induced-constipation-treatment-market">Global Opioid Induced Constipation Treatment Market</a>

<a href="https://www.datamintelligence.com/research-report/south-america-constipation-market">South America Constipation Market</a>

<ol>
	<li>Methodology and Scope
	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>Market Definition and Overview</li>
	<li>Executive Summary</li>
	<li>Market Dynamics
	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers:
			<ol>
				<li>Rising Prevalence of IBS-C, OIC, and Chronic Constipation</li>
				<li>Increasing Geriatric Population</li>
				<li>Development of Latest Drugs and Treatment Procedures</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>Increasing Dependence on Majority of Over-the-Counter (OTC) Drugs</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Industry Analysis
	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Pipeline Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Product Innovations</li>
		<li>Unmet Needs</li>
		<li>Comparative Scenario</li>
	</ol>
	</li>
	<li>By Disease Type 
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment</li>
			<li>Market Attractiveness Index, By Disease Type Segment</li>
		</ol>
		</li>
		<li>Opioid-induced constipation (OIC)
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Chronic idiopathic constipation (CIC)</li>
		<li>Irritable bowel syndrome with constipation (IBS-C)</li>
	</ol>
	</li>
	<li>By Therapeutic
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutic Segment</li>
			<li>Market Attractiveness Index, By Therapeutic Segment</li>
		</ol>
		</li>
		<li>Chloride channel activators
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Laxatives
		<ol>
			<li>Bulk-forming agents</li>
			<li>Osmotic laxatives</li>
			<li>Stimulant laxatives</li>
			<li>Others</li>
		</ol>
		</li>
		<li>GC-C Agonists</li>
		<li>Peripherally Acting Mu-Opioid Receptor Antagonists</li>
		<li>5-HT4 Receptor Agonists</li>
	</ol>
	</li>
	<li>By Distribution Channel
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment</li>
			<li>Market Attractiveness Index, By Distribution Channel Segment</li>
		</ol>
		</li>
		<li>Hospital Pharmacies
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029</li>
		</ol>
		</li>
		<li>Retail Pharmacies</li>
		<li>Online Pharmacies</li>
	</ol>
	</li>
	<li>By Country
	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>Brazil
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutic</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
		</ol>
		</li>
		<li>Argentina</li>
		<li>Colombia</li>
		<li>Peru</li>
		<li>Rest of South America</li>
	</ol>
	</li>
	<li>Competitive Landscape
	<ol>
		<li>Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Disease Type Disease Types Benchmarking</li>
		<li>List of Key Companies to Watch</li>
	</ol>
	</li>
	<li>Company Profiles
	<ol>
		<li>Takeda Pharmaceutical Company Ltd&nbsp;
		<ol>
			<li>Company Overview</li>
			<li>Disease Type Disease Type Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview&nbsp;</li>
		</ol>
		</li>
		<li>Abbott Laboratories</li>
		<li>Daewoong Pharmaceuticals</li>
		<li>AstraZeneca</li>
		<li>Sanofi</li>
		<li>Bausch Health Companies Inc.</li>
		<li>Bayer AG</li>
		<li>Janssen Pharmaceutical(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>DataM Intelligence
	<ol>
		<li>Appendix</li>
		<li>About Us and Distribution Channel</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

List of Tables

Table 1 South America Constipation Market Share, By Disease Type, 2021 &amp; 2029 (%)

Table 2 South America Constipation Market Value, By Therapeutic, 2021, 2025 &amp; 2029 ($ Million)

Table 3 South America Constipation Market Value, By Distribution Channel, 2021, 2025 &amp; 2029 ($ Million)

Table 4 South America Constipation Market Value, By Region, 2021, 2025 &amp; 2029 ($ Million)

Table 5 South America Constipation Market Value, By Disease Type, 2021, 2025 &amp; 2029 ($ Million)

Table 6 South America Constipation Market Value, By Disease Type, 2020-2029 ($ Million)

Table 7 South America Constipation Market Value, By Therapeutic, 2021, 2025 &amp; 2029 ($ Million)

Table 8 South America Constipation Market Value, By Therapeutic, 2020-2029 ($ Million)

Table 9 South America Constipation Market Value, By Distribution Channel, 2021, 2025 &amp; 2029 ($ Million)

Table 10 South America Constipation Market Value, By Distribution Channel, 2020-2029 ($ Million)

Table 11 South America Constipation Market Value, By Region, 2021, 2025 &amp; 2029 ($ Million)

Table 12 South America Constipation Market Value, By Region, 2020-2029 ($ Million)

Table 13 South America Constipation Market Value, By Disease Type, 2020-2029 ($ Million)

Table 14 South America Constipation Market Value, By Therapeutic, 2020-2029 ($ Million)

Table 15 South America Constipation Market Value, By Distribution Channel, 2020-2029 ($ Million)

Table 16 South America Constipation Market Value, By Country, 2020-2029 ($ Million)

Table 17 Takeda Pharmaceutical Company Ltd: Overview

Table 18 Takeda Pharmaceutical Company Ltd: Product Portfolio

Table 19 Takeda Pharmaceutical Company Ltd: Key Developments

Table 20 Abbott Laboratories: Overview

Table 21 Abbott Laboratories: Product Portfolio

Table 22 Abbott Laboratories: Key Developments

Table 23 Daewoong Pharmaceuticals: Overview

Table 24 Daewoong Pharmaceuticals: Product Portfolio

Table 25 Daewoong Pharmaceuticals: Key Developments

Table 26 AstraZeneca: Overview

Table 27 AstraZeneca: Product Portfolio

Table 28 AstraZeneca: Key Developments

Table 29 Sanofi: Overview

Table 30 Sanofi: Product Portfolio

Table 31 Sanofi: Key Developments

Table 32 Bausch Health Companies Inc.: Overview

Table 33 Bausch Health Companies Inc.: Product Portfolio

Table 34 Bausch Health Companies Inc.: Key Developments

Table 35 Bayer AG: Overview

Table 36 Bayer AG: Product Portfolio

Table 37 Bayer AG: Key Developments

Table 38 Janssen Pharmaceutical: Overview

Table 39 Janssen Pharmaceutical: Product Portfolio

Table 40 Janssen Pharmaceutical: Key Developments

List of Figures

Figure 1 South America Constipation Market Share, By Disease Type, 2021 &amp; 2029 (%)

Figure 2 South America Constipation Market Share, By Therapeutic, 2021 &amp; 2029 (%)

Figure 3 South America Constipation Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure 4 South America Constipation Market Share, By Region, 2021 &amp; 2029 (%)

Figure 5 South America Constipation Market Value, 2020-2029 ($ Million)

Figure 6 South America Constipation Market Y-o-Y Growth, By Disease Type, 2021-2029 (%)

Figure 7 Opioid-induced constipation (OIC): South America Constipation Market Value, 2020-2029 ($ Million)

Figure 8 Chronic idiopathic constipation (CIC): South America Constipation Market Value, 2020-2029 ($ Million)

Figure 9 Irritable bowel syndrome with constipation (IBS-C): South America Constipation Market Value, 2020-2029 ($ Million)

Figure 10 South America Constipation Market Y-o-Y Growth, By Therapeutic, 2021-2029 (%)

Figure 11 Chloride channel activators: South America Constipation Market Value, 2020-2029 ($ Million)

Figure 12 Laxatives: South America Constipation Market Value, 2020-2029 ($ Million)

Figure 13 GC-C Agonists: South America Constipation Market Value, 2020-2029 ($ Million)

Figure 14 Peripherally Acting Mu-Opioid Receptor Antagonists: South America Constipation Market Value, 2020-2029 ($ Million)

Figure 15 5-HT4 Receptor Agonists: South America Constipation Market Value, 2020-2029 ($ Million)

Figure 16 South America Constipation Market Y-o-Y Growth, By Distribution Channel, 2021-2029 (%)

Figure 17 Hospital Pharmacies: South America Constipation Market Value, 2020-2029 ($ Million)

Figure 18 Retail Pharmacies: South America Constipation Market Value, 2020-2029 ($ Million)

Figure 19 Online Pharmacies: South America Constipation Market Value, 2020-2029 ($ Million)

Figure 20 South America Constipation Market Value, 2020-2029 ($ Million)

Figure 21 South America Constipation Market Share, By Disease Type, 2021 &amp; 2029 (%)

Figure 22 South America Constipation Market Share, By Therapeutic, 2021 &amp; 2029 (%)

Figure 23 South America Constipation Market Share, By Distribution Channel, 2021 &amp; 2029 (%)

Figure 24 South America Constipation Market Share, By Country, 2021 &amp; 2029 (%)

Figure 25 Takeda Pharmaceutical Company Ltd: Financials

Figure 26 Abbott Laboratories: Financials

Figure 27 Daewoong Pharmaceuticals: Financials

Figure 28 AstraZeneca: Financials

Figure 29 Sanofi: Financials

Figure 30 Bausch Health Companies Inc.: Financials

Figure 31 Bayer AG: Financials

Figure 32 Janssen Pharmaceutical: Financials